ReviewOncotarget2017
Long non-coding RNAs: a rising biotarget in colorectal cancer.
Review in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.
- Abnormal bowel movement frequency increases the risk of rectal cancer: evidence from cohort studies with one million people.Bioscience reports · 2020Pooled it
- Targeting molecular and genetic pathways driving tumorigenesis for precision therapy in colorectal cancer.Cancer biology & therapy · 2026Review
- Long non-coding RNAs in colorectal cancer: shaping the tumour microenvironment and advancing precision oncology.Nature reviews. Gastroenterology & hepatology · 2026Review
- RNA sequencing reveals novel lncRNA modulators in gemini nanocurcumin-treated colorectal cancer cells.Scientific reports · 2025Article
- LncRNA FTX promotes colorectal cancer radioresistance through disturbing redox balance and inhibiting ferroptosisWorld journal of gastroenterology · 2025Article
- Important role of long non-coding RNA UBE2R2-AS1 in diabetes-induced renal injury.Archives of medical science : AMS · 2025Article
- LncRNAs in modulating cancer cell resistance to paclitaxel (PTX) therapy.Medical oncology (Northwood, London, England) · 2024Review
- Therapeutic and diagnostic applications of exosomes in colorectal cancer.Medical oncology (Northwood, London, England) · 2024Review
- Review
- Interplay of miRNAs and lncRNAs in STAT3 signaling pathway in colorectal cancer progression.Cancer cell international · 2024Review
- IGFL2-AS1, a Long Non-Coding RNA, Is Associated with Radioresistance in Colorectal Cancer.International journal of molecular sciences · 2023Article
- Notch-associated lncRNAs profiling circuiting epigenetic modification in colorectal cancer.Cancer cell international · 2022Review
- Curcumin Targeting Non-Coding RNAs in Colorectal Cancer: Therapeutic and Biomarker Implications.Biomolecules · 2022Review
- Review
- Identification of Key Gene Targets for Sensitizing Colorectal Cancer to Chemoradiation: an Integrative Network Analysis on Multiple Transcriptomics Data.Journal of gastrointestinal cancer · 2022Article
- Expression profiling of cancer-related long non-coding RNAs revealed upregulation and biomarker potential of HAR1B and JPX in colorectal cancer.Molecular biology reports · 2022Article
- Targeting lncRNAs of colorectal cancers with natural products.Frontiers in pharmacology · 2022Review
- Analysis of LINC01314 and miR-96 Expression in Colorectal Cancer Patients via Tissue Microarray-Based FluorescenceDisease markers · 2022Article
- Molecular Network of Colorectal Cancer and Current Therapeutic Options.Frontiers in oncology · 2022Review
- The Mechanistic Roles of ncRNAs in Promoting and Supporting Chemoresistance of Colorectal Cancer.Non-coding RNA · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a common gastrointestinal cancer, with a high incidence and high mortality. Long non-coding RNAs (lncRNAs) are involved in the development, invasion and metastasis, early diagnosis, prognosis, the chemoresistance and radioresistance of CRC through interference with mRNA activity, directly combining with proteins to regulate their activity or alter their localization, influencing downstream gene expression by inhibiting RNA polymerase and regulating gene expression as competing endogenous RNAs. Recent progress in next generation sequencing and transcriptome analysis has revealed that tissue and cancer-type specific lncRNAs could be useful prognostic markers. Here, the CRC-associated lncRNAs from recent studies until October 2016 are reviewed and multiple studies that have confirmed CRC-associated lncRNAs are summarized. This review may be helpful in understanding the overall relationships between the lncRNAs involved in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.